Inactive Instrument

Parabolic Drugs Limited

PARABDRUGS

INE618H01016

Parabolic Drugs Announces Resignation of Balbir Singh Bhasin, Nominee Director of State Bank of India

July 25, 2014 at 11:30 am

Parabolic Drugs has informed that Balbir Singh Bhasin, Nominee Director of State Bank of India (SBI) has resigned from the Board of Directors of the company with effect from July 2, 2014.

Latest news about Parabolic Drugs Limited

Parabolic Drugs Limited Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended 31 December, 2020	11/02/21	CI
Parabolic Drugs Limited Reports Unaudited Earnings Results for the Quarter and Half Year Ended September 30, 2020	07/12/20	CI
Parabolic Drugs Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2019	24/08/20	CI
Parabolic Drugs Limited Reports Unaudited Earnings Results for the Fourth Quarter and Year Ended March 31, 2020	17/07/20	CI
Parabolic Drugs Limited Reports Unaudited Earnings Results for the Quarter Ended September 30, 2018	15/02/19	CI
Parabolic Extends Submission Date For EOI’s	16/01/19	CI
Parabolic Drugs Limited Reports Unaudited Earnings Results for the Second Quarter and Half Year Ended September 30, 2018	14/11/18	CI
Parabolic Drugs Limited Announces Unaudited Earnings Results for the Quarter Ended June 30, 2018	14/08/18	CI
Parabolic Drugs Limited Announces Change of Registered/Corporate Office	21/07/18	CI
Parabolic Drugs Limited Reports Audited Standalone Earnings Results for the Fourth Quarter and Audited Standalone and Consolidated Earnings Results for the Year Ended March 31, 2018	29/05/18	CI
Parabolic Drugs Ltd. Announces Unaudited Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2017	13/02/18	CI
Parabolic Drugs Limited Announces Executive Changes	13/02/18	CI
Parabolic Drugs Limited Announces Executive Changes	20/12/17	CI
Parabolic Drugs Ltd. Announces Unaudited Standalone Earnings Results for the Second Quarter and Six Months Ended September 30, 2017	13/11/17	CI
Parabolic Drugs Ltd. Announces Unaudited Earnings Results for First Quarter Ended June 30, 2017	14/08/17	CI
Parabolic Drugs Limited Reports Audited Standalone Earnings Results for the Fourth Quarter and Audited Standalone and Consolidated Earnings Results for the Year Ended March 31, 2017	29/05/17	CI
Parabolic Drugs Ltd Appoints Ashok Kumar Jindal as CFO	10/05/17	CI
Parabolic Drugs Ltd. Announces Unaudited Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2016	10/02/17	CI
Parabolic Drugs Ltd. Announces Unaudited Standalone Earnings Results for the Second Quarter and Six Months Ended September 30, 2016	18/11/16	CI
Parabolic Drugs Limited Announces Resignation of Sandeep Sharma as Chief Financial Officer	12/11/16	CI
Parabolic Drugs Ltd. Announces Management Changes	13/08/16	CI
Parabolic Drugs Ltd. Announces Unaudited Standalone Earnings Results for First Quarter Ended June 30, 2016	13/08/16	CI
Parabolic Drugs Ltd. Announces Audited Standalone Earnings Results for the Fourth Quarter and Year Ended March 31, 2016 and Consolidated Earnings Results for the Year Ended March 31, 2016	27/05/16	CI
Parabolic Drugs Ltd. Approves the Resignation of Mallika Seth from the Post of Company Secretary	13/02/16	CI
Parabolic Drugs Ltd. Announces Unaudited Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2015	13/02/16	CI

Parabolic Drugs Limited is a holding company. The Company is an integrated, research-based, pharmaceutical manufacturer and exporter, engaged in development and manufacturing of Active Pharmaceutical Ingredients (API) and API intermediates. It is engaged in the manufacture of pharmaceuticals, medicinal chemical and botanical products. Its products and services include Cefuroxime Axetil Amorphus and Ceftriaxone Sodium Sterile. Its product portfolio includes Oral and Sterile Semi Synthetic Penicillin API, Oral and Sterile Cephalosporin API in antibiotic segment to non-antibiotic API in the Cardiovascular, Nonsteroidal anti-inflammatory drugs (NSAID), Anti-Hypertensive and Osteoporosis segments. Its products include Cefixime Trihydrate, Ceftibuten, Cefcapene Pivoxil, Cefuroxime Sodium, Amoxycillin Trihydrate, Bacampicillin Hcl, Piperacillin Sodium, Sulbactum Sodium, Deferasirox, Pentazocine, Raubasine, Yohimbine, Montelukast, Vildagliptin, Cefoxitin Sodium and Cefpodoxime Acid.

Sector

Pharmaceuticals

More about the company

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
SUN PHARMACEUTICAL INDUSTRIES LTD.	+21.01%	43.7B
OTSUKA HOLDINGS CO., LTD.	+29.65%	23.11B
SANDOZ GROUP AG	+19.88%	15.43B
CIPLA LIMITED	+19.45%	14.31B
ZYDUS LIFESCIENCES LIMITED	+55.92%	12.87B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-11.27%	6.45B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+12.21%	5.55B

Generic Pharmaceuticals